INO Earnings Prediction
The chart below shows how INO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, INO sees a +8.56% change in stock price 10 days leading up to the earnings, and a -4.60% change 10 days following the report. On the earnings day itself, the stock moves by -1.35%. This data can give you a slight idea of what to expect for the next quarter's release.
INO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
0.00
-100.00%
-100.00%
Gross Margin
--
--
--
Operating Margin
-91333.40%
1316.88%
177.22%
Net Margin
-87207.92%
898.40%
172.58%
EPS
-0.89
-41.45%
-25.21%
No Data Available
INO Earnings Analysis
Inovio Pharmaceuticals, Inc. Corporation (INO.O) Earnings Conference Call
Positive
Liquidity Management Update: Inovio closed the third quarter of 2024 with $84.8 million in cash, cash equivalents, and short-term investments, compared to $145.3 million as of December 31, 2023, indicating strong liquidity management.
Operating Expenses Reduction: The total operating expenses dropped 24% from $35.9 million in Q3 2023 to $27.3 million in Q3 2024, showcasing effective cost management strategies.
Net Loss Improvement: Inovio's net loss for Q3 2024 was $25.2 million, or $0.89 per share, compared to a net loss of $33.9 million, or $1.52 per share, in Q3 2023, reflecting improved financial performance.
BLA Submission Milestone: The company is on track to submit a Biologics License Application (BLA) for INO-3107 in mid-2025, which is a significant milestone for the product's commercialization.
Promising Trial Results: Inovio's ongoing Phase 1/2 trial for INO-3107 has shown promising results, with a significant percentage of patients reporting a reduction in surgical interventions, indicating potential clinical benefits.
Negative
Quarterly Net Loss Comparison: Inovio's net loss for the third quarter of 2024 was $25.2 million, or $0.89 per share, compared to a net loss of $33.9 million, or $1.52 per share, for the third quarter of 2023, indicating a significant ongoing financial challenge.
Operating Expenses Reduction: Total operating expenses dropped 24% from $35.9 million in the third quarter of 2023 to $27.3 million in the third quarter of 2024, reflecting cost-cutting measures but also potential impacts on operational capacity.
Cash Burn Rate Concerns: The company finished the third quarter of 2024 with $84.8 million in cash, cash equivalents, and short-term investments, down from $145.3 million as of December 31, 2023, indicating a concerning cash burn rate.
Cash Runway Concerns: Inovio's cash runway is estimated to take them into the third quarter of 2025, suggesting potential liquidity issues if additional funding is not secured soon.
Operational Cash Burn Concerns: The projected operational net cash burn estimate of approximately $24 million for the fourth quarter of 2024 raises concerns about the sustainability of current operations without further capital infusion.
INO FAQs
How does INO typically perform around its earnings report dates?
Is Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
INO Earning Call Sentiment
Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
INO.O
1.78%Positive
The earnings call reveals several concerns: significant cash depletion, ongoing losses, and unresolved manufacturing issues that could delay BLA submission. While operating expenses have decreased, regulatory and competitive risks remain high. The Q&A section highlights management's vague responses about international regulatory timelines and manufacturing resolutions, further increasing uncertainty. Despite some positive physician feedback, these factors suggest a negative sentiment, likely leading to a stock price decline between -2% to -8% over the next two weeks.